Published in Hum Gene Ther on January 26, 2012
Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr (2014) 2.07
SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE. Mol Ther Methods Clin Dev (2014) 0.83
Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Hum Gene Ther Clin Dev (2014) 0.83
Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery. Ann Neurosci (2012) 0.82
Ramped-rate vs continuous-rate infusions: An in vitro comparison of convection enhanced delivery protocols. Ann Neurosci (2013) 0.81
Slow AAV2 clearance from the brain of nonhuman primates and anti-capsid immune response. Gene Ther (2015) 0.78
Titer and product affect the distribution of gene expression after intraputaminal convection-enhanced delivery. Stereotact Funct Neurosurg (2014) 0.77
Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease. Mol Ther Methods Clin Dev (2016) 0.77
Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 0.77
Automated segmentation tool for brain infusions. PLoS One (2013) 0.77
Rapid inverse planning for pressure-driven drug infusions in the brain. PLoS One (2013) 0.76
Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson's Disease Using Tracer-based MRI. Aging Dis (2017) 0.75
Gene therapy targeting mitochondrial pathway in Parkinson's disease. J Neural Transm (Vienna) (2016) 0.75
Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 6.61
Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther (1998) 3.77
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol (2000) 2.98
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 2.37
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 1.79
A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther (2006) 1.77
A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther (2010) 1.68
Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel (2003) 1.65
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2008) 1.53
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.46
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci (1986) 1.39
Striatal volume differences between non-human and human primates. J Neurosci Methods (2008) 1.33
Risk factors for hemorrhage during microelectrode-guided deep brain stimulator implantation for movement disorders. Neurosurgery (2005) 1.32
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther (2010) 1.32
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther (2001) 1.31
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther (2010) 1.31
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg (2011) 1.30
Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods (2000) 1.27
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage (2009) 1.24
The vascular supply of the functional compartments of the human striatum. Brain (2006) 1.10
Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease. Neurosurgery (2010) 1.05
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage (2010) 1.02
Distribution of AAV2-hAADC-transduced cells after 3 years in Parkinsonian monkeys. Neuroreport (2006) 1.00
Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg (2010) 0.99
Convection-enhanced delivery for the treatment of pediatric neurologic disorders. J Child Neurol (2008) 0.98
Controlled dissemination of AAV vectors in the primate brain. Prog Brain Res (2009) 0.93
A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res (1998) 0.93
A systems approach to prion disease. Mol Syst Biol (2009) 2.49
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther (2012) 2.42
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther (2006) 2.41
Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol (2006) 2.38
Strain-specified characteristics of mouse synthetic prions. Proc Natl Acad Sci U S A (2005) 2.25
Transmission and detection of prions in feces. J Infect Dis (2008) 2.20
Diagnosis of human prion disease. Proc Natl Acad Sci U S A (2005) 2.13
Neurostimulation for traumatic brain injury. J Neurosurg (2014) 2.10
Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg (2005) 2.07
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics (2008) 1.79
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp Neurol (2005) 1.78
A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther (2006) 1.77
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc (2005) 1.74
Surgical technique of temporary arterial occlusion in the operative management of spinal hemangioblastomas. World Neurosurg (2010) 1.72
Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther (2006) 1.72
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther (2012) 1.70
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A (2009) 1.70
Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol (2010) 1.66
Prion-associated dilated cardiomyopathy. Arch Intern Med (2005) 1.66
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease. J Neurosci (2010) 1.59
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. Hum Gene Ther (2009) 1.55
Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: reciprocal networks and neuronal evolution. Alzheimer Dis Assoc Disord (2007) 1.55
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther (2012) 1.55
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage (2008) 1.53
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates. Hum Gene Ther (2013) 1.52
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther (2011) 1.50
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.46
Transmission barriers for bovine, ovine, and human prions in transgenic mice. J Virol (2005) 1.43
Inactivation of prions by acidic sodium dodecyl sulfate. J Virol (2006) 1.43
Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol Ther (2008) 1.40
Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg (2008) 1.40
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res (2006) 1.36
Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther (2009) 1.36
Current status of gene therapy trials for Parkinson's disease. Exp Neurol (2007) 1.34
Striatal volume differences between non-human and human primates. J Neurosci Methods (2008) 1.33
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther (2010) 1.32
Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp Neurol (2005) 1.32
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther (2010) 1.31
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg (2011) 1.30
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol (2006) 1.29
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol (2006) 1.26
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res (2004) 1.26
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation. J Neurosurg (2008) 1.25
Optimized cannula design and placement for convection-enhanced delivery in rat striatum. J Neurosci Methods (2009) 1.25
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage (2009) 1.24
Real-time imaging and quantification of brain delivery of liposomes. Pharm Res (2006) 1.22
Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther (2009) 1.21
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro Oncol (2007) 1.21
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol (2005) 1.17